The scientific and commercial goal of this small business innovation research (SBIR-Phase II) proposal is to develop cell-based assays for the detection of biologically active complementary and alternative medicine (CAM) agents in body fluids. The proposed project builds on the foundation of a molecular assay designed and validated through a recent Phase I funding. The strategy of identifying CAM agents in body fluids by an in vitro bio-luminescence imaging system complements another drug-discovery technology developed at Swaasth Inc, referred to as Genetic Expression and Measurement (GEMTM). Together, these cell-based CAM agent detection technologies will enable the development of novel technologies in monitoring objective measures of adherence to study-protocol in the investigations of CAM modalities. Swaasth Inc. has ? successfully developed molecular reagents and high throughput-screening infrastructure required to ? identify CAM agents. It is anticipated that the availability of GEM system will make effective use of ? the Phase II funding to further expand the detection of a variety of CAM agents and enhance ? minimally invasive patient adherence measurements for CAM modalities in clinical settings. ? ? ?
